Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic

$ 24.50

4.6 (307) In stock

Cancers, Free Full-Text

Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation

PDF) Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

PDF) Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic

Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant

View of Ciltacabtagene Autoleucel (Carvykti)

OUH - Group members

PDF) Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Biomedicines, Free Full-Text

Health-related quality of life in the ENDEAVOR study: carfilzomib- dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Biomedicines, Free Full-Text

PDF) Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

PDF) Autologous Transplantation and Maintenance Therapy in Multiple Myeloma